PeptiDream (4587.T) Stock Price
PeptiDream Price
Revenue has compounded at 37.5% per year over the past 18 years to 18.52 B JPY. Earnings per share have grown at 60.7% per year over the last 17 years. PeptiDream's net margin stands at -20.2%, down from 27.3% several years earlier. Analysts set a median price target of 2,856.00 JPY, implying 161.3% above the current price. Of 11 analysts, 10 rate the stock a buy — an overall Buy consensus.
PeptiDream stock price
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
PeptiDream business model & stock analysis
Frequently asked questions about PeptiDream
PeptiDream Inc's business model revolves around peptide drug discovery and development. The company utilizes its proprietary Peptide Discovery Platform System (PDPS) to create a wide range of non-standard peptide libraries. These libraries serve as valuable sources for identifying potential drug candidates. PeptiDream collaborates with pharmaceutical and biotech companies, enabling them to access its renowned libraries. This business model allows PeptiDream to generate revenue through licensing and milestone payments. By leveraging their expertise in peptide-based therapeutics, PeptiDream Inc aims to contribute to the development of innovative drugs and enhance treatments for various diseases.
PeptiDream Inc is primarily active in the pharmaceutical industry.
The main competitors of PeptiDream Inc in the market include Zai Lab Limited, AstraZeneca PLC, and Novartis AG.
PeptiDream Inc. is a renowned Japanese biopharmaceutical company specializing in peptide drug discovery and development. Founded in 2006, the company has established itself as a leader in the discovery and development of non-standard peptide therapeutics. PeptiDream employs its unique and proprietary Peptide Discovery Platform System (PDPS) to create a diverse library of potential drug candidates. This platform enables the rapid and efficient identification and optimization of peptide-based drugs. PeptiDream has entered into numerous partnerships with leading pharmaceutical companies globally, leveraging its expertise to explore applications in various therapeutic areas. With its innovative approach and extensive collaborations, PeptiDream continues to make significant contributions to the field of peptide drug discovery and development.
PeptiDream Inc has achieved several significant milestones. The company has successfully developed a unique peptide discovery platform called PDPS (Peptide Discovery Platform System), which enables the rapid and efficient discovery of highly diverse and functional peptide-based therapeutics. PeptiDream Inc has also established numerous collaborations with leading pharmaceutical companies to advance the development of novel peptides for various therapeutic areas. Additionally, the company has received multiple prestigious awards and recognitions for its innovative approaches and contributions to the field of peptide-based drug discovery. PeptiDream Inc continues to make remarkable progress in the discovery and development of peptide therapeutics, solidifying its position as a prominent player in the industry.
PeptiDream Inc is primarily present in Japan and the United States.
PeptiDream Inc represents values of innovation, collaboration, and excellence in the field of peptide therapeutics. The company's corporate philosophy revolves around utilizing its proprietary Peptide Discovery Platform System (PDPS) to develop novel and optimized peptides for drug discovery and development. By leveraging their cutting-edge technology and expertise, PeptiDream Inc aims to advance therapeutic options for various diseases, including cancer, metabolic disorders, and autoimmune conditions. The company emphasizes the importance of partnerships with biopharmaceutical companies, academia, and other stakeholders to accelerate the translation of discoveries into potential life-saving treatments. PeptiDream Inc's commitment to scientific advancement and breakthrough innovation drives its mission to improve global healthcare.
Analysts currently set an average price target of 3,176.57 JPY for the PeptiDream stock (median: 2,856.00 JPY), implying +197.7 % versus the latest price. The consensus is based on 11 analyst ratings.
11 analysts currently rate the PeptiDream stock: 10 recommend buying, 1 holding and 0 selling. For 2026, analysts expect PeptiDream to generate revenue of 32.57 B JPY and earnings per share of 36.50 JPY.
Converted at the current exchange rate, the PeptiDream share trades at 6.23 EUR (1,093.00 JPY).
The PeptiDream share (4587.T) is listed on 2 stock exchanges, including: Tokio (JPX) (4587.T).
The company PeptiDream Inc. is a biopharmaceutical company from Japan specialized in the discovery and development of peptide drug candidates. The company was founded in 2006 and is headquartered in Kawasaki City, Japan. PeptiDream utilizes a proprietary technology platform called Peptide Discovery Platform System (PDPS) to create and optimize specific peptide libraries used for the search of new peptide drug candidates. These peptides offer several advantages over traditional small molecules and proteins, including higher selectivity, efficacy, and stability. The company operates in three business areas: 1. Research and Development: PeptiDream collaborates with multinational pharmaceutical companies to develop new peptide drug candidates for various therapeutic applications. The company has partnerships with leading pharmaceutical companies such as Eli Lilly, Novartis, and Sanofi. 2. Standalone project business: PeptiDream also develops its own peptide drug candidates and conducts pre-clinical and clinical studies to test their efficacy and safety. The company has several programs for the development of peptide drug candidates in the areas of oncology, anti-allergy, and metabolism. 3. Platform technology: PeptiDream also offers its PDPS technology platform as a service. Companies can utilize this platform to quickly and effectively create and optimize their own peptide libraries. PeptiDream has a wide range of products utilized both for partnerships and its own development programs. Some of the products include: 1. PDPS technology: Peptide Discovery Platform System (PDPS) is a proprietary technology platform by PeptiDream. It is a fast and effective method for the creation and optimization of peptide libraries. 2. Peptide drug candidates: PeptiDream has created an extensive peptide library with potential drug candidates for various therapeutic applications. These peptides are used for drug development. 3. Peptides for partners: PeptiDream collaborates with multinational pharmaceutical companies to develop new peptide drug candidates for various therapeutic applications. The company also provides its partners with access to its peptide library and PDPS technology platform. Overall, PeptiDream is an innovative company developing peptide drug candidates for a wide range of therapeutic applications. The company has utilized its PDPS technology platform as a key to success and has established itself as a preferred partner for multinational pharmaceutical companies.
The expected revenue of PeptiDream is 32.57 B JPY. This figure is based on current financial data and reflects the company's business performance.
The expected profit of PeptiDream is 4.71 B JPY. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of PeptiDream is currently 29.94. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the PeptiDream stock.
The price-to-sales ratio (P/S) of PeptiDream is currently 4.33. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the PeptiDream stock.
The Eulerpool Quality Score for PeptiDream is 3/10.
The ISIN of PeptiDream is JP3836750004. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of PeptiDream is A1W0KK. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of PeptiDream is 4587.T. The ticker symbol is used to trade PeptiDream shares on the stock exchange.
PeptiDream stock
PeptiDream Peer Group
PeptiDream Ticker
PeptiDream FIGI
All fundamentals and in-depth analysis of PeptiDream
Our stock analysis for PeptiDream stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of PeptiDream. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.